Microbial Phenolic Metabolites in Urine Are Inversely Linked to Certain Features of Metabolic Syndrome in Spanish Adolescents
- PMID: 36358562
- PMCID: PMC9686597
- DOI: 10.3390/antiox11112191
Microbial Phenolic Metabolites in Urine Are Inversely Linked to Certain Features of Metabolic Syndrome in Spanish Adolescents
Abstract
(1) Background: To explore the association between microbial phenolic metabolites (MPM) and metabolic syndrome (MetS) and its clinical features in adolescents aged 12.02 ± 0.41 years. (2) Methods: a cross-sectional study was conducted in 560 participants at baseline in the SI! Program for Secondary Schools trial. The following MPM, coumaric acids (m-, o-, p-coumaric acids), dihydroxyphenylpropionic acid, dihydroresveratrol, enterolignans, gallic acid, hydroxybenzoic acids, hydroxyphenylacetic acid, hydroxytyrosol, protocatechuic acid, syringic acid, urolithins (A, B), and vanillic acid, were analyzed by HPLC-LTQ-Orbitrap-HRMS. MetS and its clinical features were defined in accordance with the International Diabetes Federation. (3) Results: Out of all MPM, urolithin A was inversely associated with the diastolic blood pressure z-score. Urolithin B was inversely associated with the MetS score and waist circumference z-score. Additionally, higher levels of gallic acid were associated with lower odds of presenting MetS (OR = 0.85, 95% CI: 0.77; 0.93) and abdominal obesity (OR = 0.93, 95% CI: 0.89; 0.98). Higher urolithin B levels were inversely associated with abdominal obesity (OR = 0.94, 95% CI: 0.89; 0.98) and high blood glucose (OR = 0.92, 95% CI:0.88; 0.96); (4) Conclusions: gallic acid, urolithin A and B were associated with lower odds of presenting MetS or some of its clinical features in adolescents. This is the first study that evaluates several MPM with MetS in adolescents, highlighting the importance of MPM on cardiometabolic health at early life stages.
Keywords: antioxidant compound; cardiovascular; microbiota; phytochemical.
Conflict of interest statement
R.M.L-R reports receiving lecture fees from Cerveceros de España and receiving lecture fees and travel support from Adventia and Idilia Foods SL. RE reports grants from Fundación Dieta Mediterránea (Spain), and Cerveza y Salud (Spain). Additionally, personal fees for given lectures from Brewers of Europe (Belgium), Fundación Cerveza y Salud (Spain), Pernaud-Ricard (Mexico), Instituto Cervantes, Lilly Laboratories (Spain), and Wine and Culinary International Forum (Spain), and non-financial support to organize a National Congress on Nutrition. Additionally, feeding trials with products from Grand Fountain and Uriach Laboratories (Spain). These funders had no role in the design, data collection and analyses, results, and the writing of the present cross-sectional study. The other authors declare no conflict of interest.
Figures
References
-
- Magliano D.J., Zimmet P., Shaw J.E. International Textbook of Diabetes Mellitus. John Wiley & Sons, Ltd.; Hoboken, NJ, USA: 2015. Classification of Diabetes Mellitus and Other Categories of Glucose Intolerance; pp. 1–16. - DOI
-
- Magnussen C.G., Koskinen J., Chen W., Thomson R., Schmidt M.D., Srinivasan S.R., Kivimäki M., Mattsson N., Kähönen M., Laitinen T., et al. Pediatric Metabolic Syndrome Predicts Adulthood Metabolic Syndrome, Subclinical Atherosclerosis, and Type 2 Diabetes Mellitus but Is No Better Than Body Mass Index Alone. Circulation. 2010;122:1604–1611. doi: 10.1161/CIRCULATIONAHA.110.940809. - DOI - PMC - PubMed
-
- Noubiap J.J., Nansseu J.R., Lontchi-Yimagou E., Nkeck J.R., Nyaga U.F., Ngouo A.T., Tounouga D.N., Tianyi F.L., Foka A.J., Ndoadoumgue A.L., et al. Global, Regional, and Country Estimates of Metabolic Syndrome Burden in Children and Adolescents in 2020: A Systematic Review and Modelling Analysis. Lancet Child Adolesc. Health. 2022;6:158–170. doi: 10.1016/S2352-4642(21)00374-6. - DOI - PubMed
-
- Després J.-P., Lemieux I., Bergeron J., Pibarot P., Mathieu P., Larose E., Rodés-Cabau J., Bertrand O.F., Poirier P. Abdominal Obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk. Arter. Thromb. Vasc. Biol. 2008;28:1039–1049. doi: 10.1161/ATVBAHA.107.159228. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
